Biotechnology policies

Biotechnology Statistics - Canada

 

1. Collection/compilation agency: Statistics Canada

Collection/compilation type: Annex on biotechnology activities to the Federal Scientific Expenditures and Personnel Survey.

Scope: Government.

Variables:

  • Aggregate Federal Government S&T Expenditures on Biotechnology by Activity and Performer
  • Federal Government S&T Expenditures on Biotechnology Activities, by selected Government Department or Agency and Performer
  • Federal Government R&D Expenditures on Biotechnology Activities, by selected Government Department or Agency and Performer
  • Federal Government S&T Expenditures compared to Biotechnology Expenditures, by selected Government Department or Agency and Performer
  • Federal Government R&D Expenditures compared to Biotechnology Expenditures, by selected Government Department or Agency and Performer.

Frequency: Annual.

                              ********************

2. Collection/compilation agency: Statistics Canada

Collection/compilation type: Research and Development in Canadian Industry Survey.

Sector covered: Industry.

Variables:

  • Biotechnology R&D expenditures
  • Source of Funds: Government, national sources, foreign sources (Although not biotech specific)
  • Division between capital and current expenditures (Although not biotech specific)
  • R&D by sector (5 sectors).

Frequency: Annual.

Future plans (plans for new collections, strategies, experiences, etc.): N/A.

                              ********************
 
3. The following section covers three ad hoc surveys specific to biotechnology implemented by Statistics Canada.

Collection/compilation agency:
Statistics Canada

a) Collection/compilation type: Survey of Biotechnology Use in Canadian Industries – 1996.

Variables:

  • Company information: operating revenue, sales, exports, employees
  • Biotechnologies used: 22 biotechnologies, used in operations (yes/no), number of years in use, utilisation stage (4 choices), plan to use in next two years (yes/no), no plans to use (2 reasons)
  • Capital investment in biotechnology equipment: cost category 6 by 3
    1. Selection and/or Modification of Biological Material
    2. Culture and/or Use of Biological Material
    3. Environmental Biotechnologies
  • Ranking of positive influences associated with adoption of biotechnologies (9 categories)
  • Ranking of difficulties experienced by firms in implementing biotechnologies (11 categories)
  • Ranking of benefits associated with adoption of biotechnologies (15 categories)
  • Ranking of impediments to biotechnology acquisition (20 categories)
  • Sources of information (internal and external: 14 categories)
  • Ranking of production technology vis-à-vis other Canadian producers and Producers abroad
  • Information on alliances in Canada and abroad.

Reference year: 1996.

Periodicity: Occasional.

Output:

Working Paper ST-98-05, Biotechnology Use by Canadian Industry, 1996, Antoine Rose, March 1998, http://www.statcan.ca/english/research/88F0006XIE/88F0006XIB1998005.pdf

Research Paper No. 6, Diffusion of Biotechnologies in Canada, Anthony Arundel, February 1999, http://www.statcan.ca/english/research/88F0017MIE/88F0017MIE1999006.pdf
 
b) Collection/compilation type: Biotechnology Firm Survey – 1997.

Variables:

  • Company information: biotechnology activities (yes/no)
  • Biotechnologies used: 22 biotechnologies, used in operations (yes/no), principal use (3 choices), plan to use in next three years (yes/no)
  • Choice of three bio-industry sectors that best describe firms activities (22 choices)
  • Use new process in the last 3 years (yes/no)
  • Plan to use new process in the next 3 years (yes/no)
  • Company financial information: public/private, balance sheet, revenue, expense, exports, employees, sales
  • R&D expenditures: (yes/no), applied for tax benefit (yes/no) if no why not (4 choices)
  • Strategic alliances (choice of 13 reasons): yes/no, with Canadian partner or US, EU, Asia, South/Latin America, Other
  • Human resources in biotech activities (choice of 7 positions): employed, unfilled, estimated employed in 2001
  • Human resources: Education & training programme (yes/no) estimate expenditures
  • Human resources: Co-op programs students from universities employed (yes/no)
  • Full-time person employed for human resources (yes/no)
  • Estimated staff turnover rate
  • Problems recruiting business operations staff (yes/no) if yes choice of 4 specialities
  • Problems recruiting technical/production/scientific/R&D staff (yes/no) if yes choice of 3 specialities
  • Hired personnel from outside Canada (yes/no) if yes which areas (choice of 5) if yes successful (yes/no) if no why (4 reasons)
  • Had to abandon biotech project because of IP rights (yes/no), if yes patent in Canada (yes/no)
  • Litigation related to patent infringement (yes/no), if yes number of cases
  • During last three years has firm assigned the right to use IP (four options) in Canada, outside Canada
  • During last three years has firm acquired the right to use IP (four options) in Canada, outside Canada
  • Problems for biotech commercialisation in Canada (choice of 3 issues amongst 6) and 5 types of regulations issues.
  • Financing: Capital raised (yes/no), if yes: how much. Purposes (choice of 4). Sources (choice of 7) Plan to raise capital? (yes/no), if yes: how much. Purposes (choice of 4). Sources (choice of 7)
  • Strategic decisions: Most important decisions made in 1997 and 1998 - 18 choices.

Reference year: 1997.

Periodicity: Occasional.

Comments: So far, each of the biotech surveys was occasional. However, with the last survey, this may be beginning to stabilise and some more regular periodicity may be foreseen.

Industrial Classification used: See the following table. This ad hoc classification was developed to distribute firms across biotechnology application sectors

Category: Human Health - Bio

1. Diagnostics (e.g. immunodiagnostics, gene probes, biosensors
2. Therapeutics (e.g. vaccines, immune stimulants, biopharmaceuticals, rational drug design, drug delivery, combinatorial chemistry)
3. Gene therapy (e.g. gene identification, gene constructs, gene delivery)

Category: Bio-informatics

4. Genomics and molecular modelling (e.g. DNA/RNA/protein sequencing & databases for humans, plants, animals and micro-organisms)

Category: Ag - Bio

5. Plant biotechnology (e.g. tissue culture, embryogenesis, genetic markers, genetic engineering)
6. Animal biotechnology (e.g. diagnostics, therapeutics, embryo transplantation, genetic markers, genetic engineering)
7. Biofertilizers/biopesticides/bioherbicides/biological feed additives/microbial pest control (e.g. bacteria, fungi, yeasts)
8. Non-food applications of agricultural products (e.g. fuels, lubricants, commodity and fine chemical feedstocks, cosmetics)

Category: Food processing

9. Bioprocessing (e.g. using enzymes and bacteria culture)
10. Functional foods/nutriceuticals (e.g. probiotics, unsaturated fatty acids)

Category: Aquaculture

11. Fish health (e.g. diagnostics, therapeutics)
12. Broodstock genetics (e.g. tracking superior traits, genetic modification/engineering)
13. Bioextraction (e.g. karageenan from seaweed, antifreeze proteins from fish, flavours)

Category: Mining/energy/petroleum/chemicals

14. Microbiologically enhanced petroleum/mineral recovery
15. (Cleaner) industrial bioprocessing (e.g. biodesulphurization, bio-cracking, bio-recovery)

Category: Forest products

16. Silviculture (e.g. ectomycorrhizae, tissue culture, somatic embryogenesis, genetic markers, genetic engineering)
17. (Cleaner) industrial bioprocessing (e.g. biopulping, biobleaching, biological prevention of sapstain)

Category: Environment

18. Biofiltration (e.g. treatment of organic emissions to air/water)
19. Bioremediation and phytoremediation (e.g. cleanup of toxic waste sites using micro-organisms)
20. Diagnostics (e.g. detection of toxic substances using bioindicators, biosensors, immunodiagnostics)

Category: Other

21. Custom synthesis - chemical or biological (e.g. peptides, proteins, nucleotides, hormones, growth factors, biochemicals)
22. Other (please specify)

Definition used: Rather than defining biotechnology, Canada has established a list of 22 biotechnologies. A firm becomes a biotechnology user when it uses at least one biotechnology from a list of biotechnology activities. The list for the Biotechnology Firm Survey - 1997 is the following:

DNA based

Genetic engineering

 

Gene probes

 

Bio-informatics/genomics/pharmacogenetics

 

DNA sequencing/synthesis/amplification

 

Gene therapy

Biochemistry/immunochemistry based

Vaccines/immune stimulants/drug design & delivery/combinatorial chemistry

 

Diagnostics tests/antibodies

Peptide/protein sequencing or synthesis

 

Cell receptors/cell signalling/pherormones/three dimensional molecular modelling/structural biology

 

Biosensors

 

Biomaterials

 

Microbiology/Virology/Microbial ecology

Bioprocessing based

Cell/tissue/embryo culture & manipulation

 

Fermentation/bioprocessing/biotransformation/
bioleaching/biopulping/biobleaching/
biodesulphurization

 

Extraction/purification/separation

 

Bioremediation/phytoremediation/biofiltration/
bioindicators

 

Natural product chemistry

c) Collection/compilation type: Biotechnology Use and Development Survey – 1999.

Variables:

  • Biotechnologies used: 22 biotechnologies, used in operations (yes/no), principal use (3 choices), plan to use in next three years (yes/no)
  • If firm does not use biotechnology – ranking of barriers to using (12 categories)
  • Ranking of sources of information (internal and external: 12 categories)
  • Ranking of benefits associated with adoption of biotechnologies (13 categories)
  • Human resources in biotech activities: number of employees, number of employees with biotech-related responsibilities
  • Human resources in biotech activities (choice of 7 positions): full-time, part-time, estimated employed in 2002
  • Human resources in biotech activities (choice of 7 positions): unfilled full-time and choice of three options for the reason
  • Does your firm employ (either paid or unpaid) post-secondary students in biotechnology-related activities? Include co-op placements, part-time, and full-time positions (yes/no) – if yes: level of education (choice of three)
  • Does your firm contract out any of the following biotechnology-related activities? (yes/no) (4 activities) if yes: value of contracts?
  • Recruiting Practices: methods used to fill biotechnology-related positions (choice of 11)
  • Hired personnel from outside Canada (yes/no) if yes which areas (choice of 5) if yes successful (yes/no) if yes how many
  • Did biotechnology personnel leave your firm in 1999?
  • Product/Process Development: Is your firm currently developing product that requires the use of biotechnologies? (yes/no)
  • Is your firm currently developing processes that requires the use of biotechnologies? (yes/no)
  • Does your firm consider biotechnology central to its activities? (yes/no)
  • Biotechnology Products: Please provide the number of biotechnology products or processes your firm has at each stage of development. (Industrial Classification list similar to the one above) and by Number of biotechnology products/processes by development stage (choice of 4)
  • Was your firm involved in biotechnology-related co operative/collaborative arrangements with other companies or organizations? (yes/no) if yes how many
  • For what purpose? (choice of 8 arrangement purposes)
  • By geographic location: with Canadian partner or USA, EU, Asia, South/Latin America, Other and Partner category (5 types)
  • Would you describe your firm as a “spin-off”? (yes/no) if yes from (choice of 4)
  • Ranking of Obstacles to Biotechnology Commercialization (15 choices)
  • Patents: Existing and Pending by Geographic location
  • Patent applications - choice of three patent offices and other
  • Number of applications for plant breeders’ rights your company submitted – choice of three offices and other
  • During last two years has firm assigned or acquired the right to use IP (four options) in Canada, outside Canada (three types of IP)
  • Company information: operating revenue, sales, exports, imports
  • Biotech Exports to what geographic locations (choice of 5)
  • Biotech Imports from what geographic locations (choice of 5)
  • Attempt to raise capital (yes/no) if yes source of capital (choice of 7)
  • Intention to raise capital in 2002 (yes/no) if yes how much (choice of 3)
  • Apply for tax benefit in past 5 years (yes/no) if no why not (choice of 4)
  • Does your firm use Internet (yes/no) if yes for what purposes (choice of 9)
  • Strategic decisions: 14 choices.

Reference Year: 1999.

Periodicity: Occasional.

Output:

Working Paper ST-01-07, Biotechnology Use and Development, 1999, Chuck McNiven, March 2001, http://www.statcan.ca/english/research/88F0006XIE/88F0006XIB2001007.pdf

Working Paper ST-01-11, Practices and Activities of Canadian Biotechnology Firms: Results from the Biotechnology Use and Development Survey - 1999, Chuck McNiven, August 2001, http://www.statcan.ca/english/research/88F0006XIE/88F0006XIB2001011.pdf

Working Paper ST-02-03, Use of Biotechnologies in the Canadian Industrial Sector: Results from the Biotechnology Use and Development Survey - 1999, Chuck McNiven, March 2002, http://www.statcan.ca/english/research/88F0006XIE/88F0006XIE2002003.pdf

Working Paper ST-02-04, Profile of Spin-off Firms in the Biotechnology Sector: Results from the Biotechnology Use and Development Survey - 1999, Craig Byrd, March 2002, http://www.statcan.ca/english/research/88F0006XIE/88F0006XIE2002004.pdf

Future plans (plans for new collections, strategies, experiences etc.): N/A

Contact details:

http://www.statcan.ca

http://strategis.ic.gc.ca

d) Collection/compilation type: Survey of Biotechnology Use in Canadian Industries – 2001

Variables:

  • Biotechnologies used: 22 biotechnologies, used in operations (yes/no), principal use (3 choices), number of years in use, plan to use in next three years (yes/no)
  • If firm does not use biotechnology – return the questionnaire
  • The effects of biotechnology on your firm: The level of influence of each factor on increasing your use of biotechnology (5 degrees), the level of impacts of biotechnology use on your firm’s performance (5 degrees)
  • Human resources in biotech activities: number of employees, number of employees with biotechnology-related responsibilities, number of full-time biotechnology employees (7 positions and total), number of part-time biotechnology employees (7 positions and total)
  • Recruiting practices: unfilled biotechnology-related positions (yes/no), if yes: the number of unfilled positions by category (choice of 7 positions)
  • Recruiting practices: Did you attempt to recruit any biotechnology employees in 2001?(yes/no), if yes, successful (yes/no), if yes, number of employees, sources used in recruiting (choice of 11)
  • The impact of factors on your efforts in filling biotechnology-related vacancies (choice of 7)
  • Hired personnel from outside Canada (yes/no), if yes successful (yes/no) if yes how many
  • Human resources in biotech activities: Did biotechnology personnel leave your firm in 2001? (yes/no) - if yes, number of biotechnology personnel that left
  • Biotechnology products: Do you have biotechnology product/process on the market? (yes/no), if yes, what year was the most significant product first introduced?
  • Biotechnology products: Is your firm currently developing products that require the use of biotechnologies? (yes/no), if yes, what year will the most significant of these products reach market?
  • Is your firm currently developing processes that require the use of biotechnologies? (yes/no) If yes, what year will the most significant of these processes be completed?
  • Does your firm consider biotechnology central to its activities? (yes/no)
  • Biotechnology Products: Please provide the number of biotechnology products or processes your firm has at each stage of development. (Industrial Classification list similar to the one above) and by Number of biotechnology products/processes by development stage (choice of 4)
  • What is the total time required to bring your principal biotechnology product or process from the initial development phase/proof of concept stage to the market? What is the total cost to bring it to the market?
  • Business practices: Did your firm contract out biotechnology related activities in 2001? (yes/no), if yes, type of partner (private/public), numbers of contracts and total value of contract in 2001 by purpose of contract (choice of 4)
  • Did you contract out to organizations outside of Canada? (yes/no), if yes, indicate the percentage (%) of your firm’s total contracting out by organization (choice of 5)
  • Business practices: level of importance of each of the following reasons on your decision to contract out (choice of 8 reasons and 5 degrees)
  • Does your firm provide contract services to other firms or organizations (yes/no); if yes number of contracts entered in 2001, revenue received and sources of the contract (choice of 5 sources)
  • Was your firm involved in biotechnology-related cooperative/collaborative arrangements with other companies or organizations? (yes/no) if yes number of arrangements by partner type (choice of 4) and by arrangement purpose (choice of 8)
  • Intellectual property: Did your firm grant biotechnology related intellectual property rights to another firm? (yes/no) if yes the number of IP rights by type of IP (choice of 3 IP instruments) and by country (choice of 3); Revenue from IP licensing in 2001
  • Did your firm obtain biotechnology related intellectual property rights from another firm? (yes/no) If yes, the number by type of IP and by country; Cost to your firm of obtaining IP in 2001
  • Patents: Existing and Pending by Patent office, number of unique patent applications your company submitted in 2000 and 2001
  • Firm characteristics and financial profile: revenue, research and Development expenditures and % of biotechnology R&D spending contracted out in 2000 in 2001 and forecast of 2004
  • Sales of biotechnology products (yes/no), if yes, percentage of your sales by type of clients (choice of 2)
  • Firm history: Is your firm a public firm? (yes/no), if yes, what year was the Initial Public Offering?
  • What year was your firm or spin-off established?
  • Merger with another firm (yes/no), if yes, what year
  • Is your firm a subsidiary of a multinational enterprise?
  • Is your firm a spin-off? (yes/no), if yes, from (choice of 5)
  • Attempt to raise capital (yes/no) if yes how much, target reached (yes/no) If no, reasons given by lender (choice of 7), source of funding (choice of 7)
  • The main product or process: Current stage of development (choice of 4), total spending and spending by stage of development, total amount of the capital required to complete each stage
  • How long do you anticipate this capital? (In years and months)
  • Reasons for raising/attempting to raise capital (6 choices)
  • Do you plan  to raise capital in 2002 (yes/no), if yes how much (choice of 3)
  • Apply for tax benefit in past 5 years (yes/no), if yes, how much, if no why not (choice of 4), have any of your SR&ED credits expired? (yes/no)
  • Apply for provincial R&D tax benefit or incentive?(yes/no), if no, reasons (choice of 4)
  • Exports (yes/no) if yes, value and percentage of exports, by geographic location (choice of 4) for 2000, 2001 and a 2004 forecast
  • Imports (yes/no), if yes, value and percentage of imports, by geographic location (choice of 4) for 2000, 2001 and a 2004 forecast
  • Strategies used in 2001 (12 choices of strategies and 5 degrees)
  • Development, production or sale of Living Modified Organisms (yes/no), if yes, how many, by stages (choice of 3)
  • Exports of LMO (yes/no), if yes, how many and geographic location (choice of 3)

Reference year: 2001.

Periodicity: Occasional.

Output:
Working Paper ST-03-05, Features of Canadian Biotech Innovative Firms: Results from the Biotechnology Use and Development Survey - 2001, Chuck McNiven, Lara Raoub and Namatié Traoré, March 2003, http://www.statcan.ca/english/research/88F0006XIE/88F0006XIE2003005.pdf

Working Paper ST-03-13, Bioproducts Development by Canadian Biotechnology Firms: Findings from the 2001 Biotechnology Use and Development Survey, Namatié Traoré, December 2003

Future plans (plans for new collections, strategies, experiences etc.): N/A

Contact details:

http://www.statcan.ca
http://strategis.ic.gc.ca

Survey attached in annex

e)
Collection/compilation type: Survey of Biotechnology Use in Canadian Industries – 2003

Variables:

  • Biotechnologies used: 9 biotechnologies, used in operations (yes/no), principal use (3 choices), number of years in use, plan to use in next three years (yes/no)
  • If firm does not use biotechnology - go to section 7: bioproducts
  • Human resources in biotechnology activities: number of employees in Canada, number of employees with biotechnology-related responsibilities, number of full-time biotechnology employees (7 positions and total), number of part-time biotechnology employees (7 positions and total)
  • Recruiting practices: unfilled biotechnology-related positions (yes/no), if yes: the number of unfilled positions by category (choice of 7 positions)
  • Recruiting practices: Did you attempt to recruit any biotechnology employees in 2003 ?(yes/no), if yes, successful (yes/no), if yes, number of employees
  • Recruiting practices: Did you attempt to recruit any biotechnology employees from outside of Canada in 2003?(yes/no), if yes, number of employees hired by country/region
  • The impact of factors on your efforts in filling biotechnology-related vacancies (7 factors)
  • Human resources in biotech activities: Did biotechnology personnel leave your firm in 2003? (yes/no) - if yes, number of biotechnology personnel that left
  • Firm history: what year was your firm established? Is your firm a public firm? (yes/no) If yes, what year was the Initial Public Offering?
  • Merger with another firm (yes/no), if yes, what year?
  • Is your firm a subsidiary of a Multi-National enterprise?
  • Is your firm a spin-off? (yes/no), if yes, from: (choice of 5)
  • Biotechnology products: Do you have biotechnology product/process on the market? (yes/no)
  • Is your firm currently developing products that require the use of biotechnologies? (yes/no)
  • Is your firm currently developing processes that require the use of biotechnologies? (yes/no)
  • Does your firm consider biotechnology central to its activities? (yes/no)
  • Biotechnology: number of biotechnology products/processes by development stage (choice of 4) and by sector (17 categories)
  • Did you have biotechnology products or processes in any stage of R&D? (yes/no) If yes, number of products or processes
  • Principal product or process: current stage of development (choice of 3), how long has it been under development? (in years and months), how much did you invest in R&D ?
  • Did you have any biotechnology products or processes in production or on the market? (yes/no) if yes, number of products or processes. What is the total time required to bring your principal biotechnology product or process from the initial development phase/proof of concept stage to the market? (in years and months) What is the total cost to bring it to the market?
  • Business practices: Did your firm contract out biotechnology related activities in 2003? (yes/no), if yes, type of partner (choice of 5), number of contracts and total value of contract in 2003 by purpose of contract (choice of 4)
  • Did contracting out in 2003 replace biotechnology employees in your firm? (yes/no), if yes, number of employees by type of position (choice of 7)
  • Business practices: level of importance of each of the following reasons on your decision to contract out (choice of 7 reasons and 5 degrees)
  • Does your firm provide contract services to other firms or organizations (yes/no); if yes, number of contracts entered into in 2003, revenues received and sources of the contract (choice of 5 sources)
  • Was your firm involved in biotechnology-related cooperative/collaborative arrangements with other companies or organizations? (yes/no) if yes number of arrangements by partner type (choice of 4) and by arrangement purpose (choice of 8)
  • Was your firm involved in biotechnology-related cooperative/collaborative arrangements with foreign companies or organizations? (yes/no) if yes, number of arrangements by partner type (choice of 5) and by geographic location (choice of 4), reasons by arrangement purpose (choice of 8 and 5 degrees for each purpose)
  • Patents? (yes/no) if yes, the number, Existing and Pending by Patent office, number of unique patent applications your company submitted in 2002 and 2003
  • Intellectual property: Did your firm grant biotechnology related intellectual property rights to another firm? (yes/no) if yes the number of IP rights by type of IP (choice of 4 IP instruments) and by country (choice of 3); Revenue from IP licensing in 2003
  • Did your firm obtain biotechnology related intellectual property rights from another firm? (yes/no) if yes, the number by type of IP (choice of 4) and by country (choice of 3); Cost to your firm of obtaining IP in 2003
  • Firm characteristics and financial profile: revenue, Research and Development expenditures and % of biotechnology R&D spending contracted out in 2002 in 2003 and forecast of 2005
  • Attempt to raise capital (yes/no) if yes, what were the reasons (choice of 6), were you successful (yes/no) if yes, how much, was target reached (yes/no) if no, reasons given by lender (choice of 7), source of funding (choice of 10)
  • Do you plan  to raise capital in 2004 (yes/no) if yes how much (choice of 3)
  • Apply for tax benefit in past 5 years (yes/no) if yes, how much did you apply for and how much did you receive, if no why not (choice of 4), have any of your SR&ED credits expired? (yes/no)
  • Apply for provincial R&D tax benefit or incentive? (yes/no) if no, reasons (choice of 4)
  • Exports of biotech products? (yes/no) if yes, value and percentage of exports, by geographic location (choice of 4) for 2002, 2003 and a 2005 forecast
  • Imports of biotech products? (yes/no) if yes, value and percentage of imports, by geographic location (choice of 4) for 2002, 2003 and a 2005 forecast
  • Bioproducts: Does your firm currently make or develop any bioproduct? (yes/no), if yes, number of bioproducts by category (choice of 8) and by stage of development (choice of 3)
  • Current use of renewable or sustainable feedstock/materials? (yes/no), if yes, check the type (choice of 7)
  • Financial profile: revenue (total and from bioproducts), exports from bioproducts, imports of bioproducts, R&D in 2002 in 2003 and forecast of 2005
  • Human resources in bioproducts development: number of employees in Canada, number of employees with bioproducts-related activities, number of full-time employees with bioproducts-related activities, number of part-time employees with bioproducts-related activities
  • Strategies used in 2003 (12 choices of strategies and 5 degrees)
  • Time to complete the questionnaire.

Reference Year: 2003.

Periodicity: Occasional.

Output:

http://www.statcan.ca/Daily/English/041214/d041214d.htm

http://www.statcan.ca/Daily/Francais/041214/q041214d.htm

Survey attached in  annex

                              ********************

4. Collection/compilation agency:
Canadian Department of Foreign Affairs and International Trade has documents on biotechnology in different counties: Australia, Japan (http://www.dfait-maeci.gc.ca/ni-ka/scitech/biotech-e.asp), Germany, Ireland, Korea, Mexico, the United Kingdom, the United States, etc.

Collection/compilation type: Market studies.

Variables:

  • Number of employees
  • Predicted employment in 2000
  • Useful Internet sites.

Scope: National.

Frequency: N/A

Periodicity: N/A

Classification used: None.

Definition used: N/A

Output: Documents on biotechnology in different countries.

Contact comments: Market studies with some basic data and the evolution of biotechnology for the countries are generally available.

Future plans (plans for new collections, strategies, experiences etc.): N/A

Contact details: http://www.dfait-maeci.gc.ca/

 

 

 

Countries list

  • Afghanistan
  • Albania
  • Algeria
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Brazil
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China (People’s Republic of)
  • Chinese Taipei
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Croatia
  • Cuba
  • Cyprus
  • Czech Republic
  • Côte d'Ivoire
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • Dominican Republic
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • European Union
  • Faeroe Islands
  • Fiji
  • Finland
  • Former Yugoslav Republic of Macedonia (FYROM)
  • France
  • French Guiana
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iraq
  • Ireland
  • Islamic Republic of Iran
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jersey
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kuwait
  • Kyrgyzstan
  • Lao People's Democratic Republic
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Libya
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macao (China)
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia (Federated States of)
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestinian Administered Areas
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Romania
  • Russian Federation
  • Rwanda
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Vincent and the Grenadines
  • Samoa
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Serbia and Montenegro (pre-June 2006)
  • Seychelles
  • Sierra Leone
  • Singapore
  • Slovak Republic
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Sudan
  • Spain
  • Sri Lanka
  • Sudan
  • Suriname
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • Tajikistan
  • Tanzania
  • Thailand
  • Timor-Leste
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Virgin Islands
  • Uruguay
  • Uzbekistan
  • Vanuatu
  • Venezuela
  • Vietnam
  • Virgin Islands (UK)
  • Wallis and Futuna Islands
  • Western Sahara
  • Yemen
  • Zambia
  • Zimbabwe
  • Topics list